Vol. 6 No. 3 (2026)
Reimbursement Reviews

Amivantamab (Rybrevant)

decorative image of the issue cover

Published March 18, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Amivantamab (Rybrevant); 350 mg/7 mL (50 mg/mL) single-use vial for IV infusion.
  • Indication: Amivantamab (Rybrevant) in combination with carboplatin and pemetrexed for the treatment of patients with locally advanced (not amenable to curative therapies) or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.